Yeung J H, Chiu L C, Ooi V E
Department of Pharmacology, Chinese University of Hong Kong, Shatin.
Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):287-92. doi: 10.1007/BF03190246.
The effect of polysaccharide peptide (PSP), an immunomodulator isolated from Coriolus versicolor COV-1, on the disposition of paracetamol was investigated in the rat. PSP (100 and 200 mg/kg, i.v.) was administered 30 min before a moderate dose (100 mg/kg, i.v.) of paracetamol was given. Plasma and bile concentrations of paracetamol, paracetamol glucuronide and paracetamol sulphate were measured by high performance liquid chromatography. The pharmacokinetics of paracetamol (100 mg/kg) alone was consistent with those reported previously, using a one-compartment model. PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively. These changes were associated with concomitant increases in the glucuronide and sulphate metabolites in plasma, with significant increases in the Cmax and Tmax for both metabolites. The biliary excretion rate of paracetamol glucuronide and paracetamol sulphate were also measured. The Cmax values of paracetamol sulphate were significantly (P < 0.01) increased by 2.4-fold from 907.8 +/- 157.7 micrograms/ml (controls) to 3061 +/- 331 micrograms/ml after PSP treatment. The lower dose of PSP (100 mg/kg) had no significant effect on the disposition of paracetamol in this study, which agreed with previous reports that a low dose of PSP (100-200 mg/kg, i.p.) was less effective in the protection against paracetamol-induced hepatotoxicity. The time course of the increase in paracetamol sulphate in plasma and bile in this study coincided with the transient perturbation of glutathione (GSH) turnover by a similar dose range of PSP previously described, such that more cysteine was available for oxidation to inorganic sulphate. This increase in sulphate conjugation by PSP would, in part, contribute to the increase in disposition of paracetamol and may be related to the ability of PSP to decrease the covalent binding of paracetamol to microsomal proteins previously reported. Further studies are necessary to understand the mechanism(s) involved in the PSP-induced increases in paracetamol glucuronide and paracetamol sulphate formation and biliary excretion.
研究了从云芝COV - 1中分离出的免疫调节剂多糖肽(PSP)对大鼠体内扑热息痛处置的影响。在给予中等剂量(100 mg/kg,静脉注射)的扑热息痛前30分钟,静脉注射PSP(100和200 mg/kg)。采用高效液相色谱法测定血浆和胆汁中扑热息痛、扑热息痛葡萄糖醛酸苷和扑热息痛硫酸酯的浓度。单独使用扑热息痛(100 mg/kg)的药代动力学与先前报道一致,符合一室模型。PSP(200 mg/kg)显著(P < 0.05)提高了扑热息痛的清除率(对照组为19.06±2.74 ml/min/kg;PSP处理组为26.22±0.84 ml/min/kg)和分布容积(对照组为1.35±0.11 l/kg;PSP处理组为1.61±0.04 l/kg),分别提高了37%和21%。这些变化伴随着血浆中葡萄糖醛酸苷和硫酸酯代谢物的相应增加,两种代谢物的Cmax和Tmax均显著增加。还测定了扑热息痛葡萄糖醛酸苷和扑热息痛硫酸酯的胆汁排泄率。PSP处理后,扑热息痛硫酸酯的Cmax值显著(P < 0.01)增加了2.4倍,从907.8±157.7微克/毫升(对照组)增至3061±331微克/毫升。在本研究中,较低剂量的PSP(100 mg/kg)对扑热息痛的处置没有显著影响,这与先前的报道一致,即低剂量的PSP(100 - 200 mg/kg,腹腔注射)在预防扑热息痛诱导的肝毒性方面效果较差。本研究中血浆和胆汁中扑热息痛硫酸酯增加的时间进程与先前描述的相似剂量范围的PSP对谷胱甘肽(GSH)周转的短暂扰动相吻合,从而使更多的半胱氨酸可用于氧化为无机硫酸盐。PSP引起的硫酸盐结合增加部分有助于扑热息痛处置的增加,并且可能与PSP降低先前报道的扑热息痛与微粒体蛋白共价结合的能力有关。有必要进行进一步研究以了解PSP诱导扑热息痛葡萄糖醛酸苷和扑热息痛硫酸酯形成及胆汁排泄增加所涉及的机制。